ALTO 101
Alternative Names: ALTO-101T TDS; ALTO-101; ALTO-101TLatest Information Update: 13 Apr 2026
At a glance
- Originator Alto Neuroscience
- Class Antipsychotics; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Schizophrenia
- Discontinued Neurodegenerative disorders; Psychiatric disorders
Most Recent Events
- 13 Apr 2026 ALTO 101 is available for licensing as of 02 Apr 2026. http://sntpseditorial/AdisCAWeb/Item.mvc/View/13595601/3949870#
- 02 Apr 2026 Clinical trials in Schizophrenia in USA (PO), prior to April 2026
- 02 Apr 2026 Efficacy, adverse event and pharmacokinetic data from a phase II trial in Schizophrenia released by Alto Neuroscience